全文获取类型
收费全文 | 199篇 |
免费 | 7篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 5篇 |
妇产科学 | 2篇 |
基础医学 | 25篇 |
临床医学 | 14篇 |
内科学 | 39篇 |
皮肤病学 | 4篇 |
神经病学 | 49篇 |
特种医学 | 13篇 |
外科学 | 20篇 |
综合类 | 1篇 |
预防医学 | 3篇 |
眼科学 | 1篇 |
药学 | 19篇 |
肿瘤学 | 9篇 |
出版年
2023年 | 1篇 |
2021年 | 5篇 |
2020年 | 5篇 |
2019年 | 7篇 |
2018年 | 5篇 |
2017年 | 3篇 |
2016年 | 5篇 |
2015年 | 7篇 |
2014年 | 2篇 |
2013年 | 4篇 |
2012年 | 15篇 |
2011年 | 20篇 |
2010年 | 7篇 |
2009年 | 7篇 |
2008年 | 11篇 |
2007年 | 21篇 |
2006年 | 11篇 |
2005年 | 6篇 |
2004年 | 7篇 |
2003年 | 13篇 |
2002年 | 9篇 |
2001年 | 1篇 |
2000年 | 1篇 |
1999年 | 1篇 |
1998年 | 3篇 |
1996年 | 2篇 |
1995年 | 1篇 |
1994年 | 1篇 |
1991年 | 3篇 |
1989年 | 4篇 |
1988年 | 2篇 |
1987年 | 3篇 |
1986年 | 1篇 |
1985年 | 1篇 |
1982年 | 1篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1973年 | 1篇 |
1971年 | 2篇 |
1970年 | 1篇 |
1969年 | 1篇 |
1968年 | 2篇 |
1967年 | 1篇 |
排序方式: 共有206条查询结果,搜索用时 15 毫秒
21.
Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis 总被引:2,自引:0,他引:2
Feuillet L Reuter F Audoin B Malikova I Barrau K Cherif AA Pelletier J 《Multiple sclerosis (Houndmills, Basingstoke, England)》2007,13(1):124-127
Cognitive impairment in patients with multiple sclerosis (MS) is a common occurrence and is generally fairly circumscribed. The prevalence of the cognitive deficits usually encountered could vary with the clinical course of the disease. To investigate whether the presence of cognitive impairment may occur in the very early stage of MS, we assessed the cognitive status of a group of 40 patients presenting with a recently diagnosed clinically isolated syndrome suggestive of MS (CISSMS), in comparison with 30 age-, sex-, and educational level-matched healthy control subjects. An extensive battery of neuropsychological tests was used to explore verbal and non-verbal memory, attention, concentration, speed of information processing, language and abstract reasoning. Patients with CISSMS had a significant, frequent (57%), and circumscribed cognitive impairment, focused on memory, speed of information processing, attention and executive functions. 相似文献
22.
Krishna R Bergman A Larson P Cote J Lasseter K Dilzer S Wang A Zeng W Chen L Wagner J Herman G 《Journal of clinical pharmacology》2007,47(2):165-174
Sitagliptin (MK-0431) is an orally active, potent, and selective dipeptidyl peptidase-4 inhibitor used for the treatment of patients with type 2 diabetes mellitus. Sitagliptin has been shown to be a substrate for P-glycoprotein in preclinical studies. Cyclosporine was used as a probe P-glycoprotein inhibitor at a high dose to evaluate the potential effect of potent P-glycoprotein inhibition on single-dose sitagliptin pharmacokinetics in healthy male subjects. Eight healthy young men received a single oral 600-mg dose of cyclosporine with a single 100-mg oral sitagliptin dose and a single oral 100-mg sitagliptin dose alone in an open-label, randomized, 2-period, crossover study. Single doses of sitagliptin with or without single doses of cyclosporine were generally well tolerated. The sitagliptin AUC(0-infinity) geometric mean ratio was 1.29 with a 90% confidence interval of (1.24, 1.34). The sitagliptin Cmax geometric mean ratio was 1.68 with a 90% confidence interval of (1.35, 2.08). Cyclosporine coadministration did not appear to affect apparent sitagliptin renal clearance, t(1/2), or C(24 h), suggesting that effects of these high doses of cyclosporine are more likely due to enhanced absorption of sitagliptin, potentially through inhibition of intestinal P-glycoprotein. These results rationalize the use of a single high-dose cyclosporine as a probe inhibitor of P-glycoprotein for compound candidates whose elimination is less dependent on CYP3A4-mediated metabolism. 相似文献
23.
Jennifer J. Schoch MD Josee Gauthier Raad Z. Gharaibeh PhD Christian Jobin PhD Mary Bohannon MHS Josef Neu MD Leslie Parker PhD 《Pediatric dermatology》2023,40(1):129-131
Despite advances in our understanding of the human microbiome, there exist significant knowledge gaps in our understanding of the skin microbiome of the preterm neonate. Herein, we describe skin microbiome sampling of six preterm neonates at multiple timepoints, and compare the skin microbiome samples to environmental (crib/isolette swabs) and negative controls. Samples of the same type (skin, crib, control) were more similar than when compared by week or by patient. 相似文献
24.
25.
Variable sensitivity and specificity of TTF-1 antibodies in lung metastatic adenocarcinoma of colorectal origin. 总被引:3,自引:0,他引:3
26.
Immunization with recombinant Sao protein confers protection against Streptococcus suis infection 下载免费PDF全文
Li Y Gottschalk M Esgleas M Lacouture S Dubreuil JD Willson P Harel J 《Clinical and Vaccine Immunology : CVI》2007,14(8):937-943
Sao is a Streptococcus suis surface protein recently identified as a potential vaccine candidate. In this study, recombinant Sao in combination with Quil A provided cross-protection against S. suis serotype 2 disease in mouse and pig vaccination protocols. Subcutaneous immunization of mice elicited strong immunoglobulin G (IgG) antibody responses. All four IgG subclasses were induced, with the IgG2a titer being the highest, followed by those of IgG1, IgG2b, and IgG3. Challenge of the mice with S. suis strain 31533 resulted in a mortality rate of 80% for the control group, which received Quil A only. In contrast, all of the mice immunized with Sao survived. In a pig vaccination protocol, intramuscular immunization with Sao also elicited significant humoral antibody responses, and both the IgG1 and IgG2 subclasses were induced, with a predominance of IgG2 production. In vitro assay showed that Sao-induced antibodies significantly promoted the ability of porcine neutrophils in opsonophagocytic killing of S. suis. An aerosol challenge of the pigs with S. suis strain 166 resulted in clinical signs characteristic of S. suis infection in diseased pigs. The vaccine group showed significantly better survival, lower clinical scores, and less S. suis recovery from postmortem tissue samples than did the control group. Furthermore, this study also revealed that although challenge S. suis strains express Sao size variants, recombinant Sao conferred cross-protection. These data demonstrate that recombinant Sao formulated with Quil A triggers strong opsonizing antibody responses which confer efficient immunity against challenge infection with heterologous S. suis type 2. 相似文献
27.
28.
29.
Serum melatonin measured by radioimmunoassay in healthy subjects at 8 a.m. was found to undergo bimodal annual variations with peaks in January and July. This annual rhythm may represent changes in total secretion or phase shifts in the circadian rhythm. 相似文献
30.